The Targeted Agent and Profiling Utilization Registry (TAPURTM) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
The study provides FDA-approved targeted therapies contributed by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists, and aims to identify potential signals of drug activity.
For more information about the TAPUR Study, please visit the ASCO website.
The TAPUR Study is open and enrolling patients at 251 clinical sites. Most of the clinical sites are part of a larger network, and all questions and/or referrals should be directed to the primary contact at the main operations center.
“I am proud that ASCO is at the forefront of creating opportunities for people with cancer and oncology clinicians to participate in research. The TAPUR Study is providing a unique opportunity to increase our understanding and expanding the reach of precision medicine in oncology.”– Dr. Bruce E. Johnson, MD, FASCO, 2017–18 ASCO President
ASCO, as the primary study sponsor and coordinating center, manages all aspects of the study, including the participation of collaborators and the selection and oversight of participating sites and vendors central to the TAPUR Study’s success.